Effect of Supplementing a Mixed Macronutrient Beverage With Graded Doses of Leucine on Myofibrillar Protein Synthesis

NCT ID: NCT01885429

Last Updated: 2013-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Muscle mass is normally maintained through the regulated balance between the processes of protein synthesis (i.e. making new muscle proteins) and protein breakdown (breaking down old muscle proteins). Proteins are composed of amino acids and we know that amino acids increase muscle protein synthesis. However, not all amino acids are the same. Essential amino acids are ones that must be consumed through food, while non-essential amino acids can be made by our body. Interestingly, the essential amino acids are all that are required to increase the rate of muscle protein synthesis. In addition, the essential amino acid leucine appears to be particularly important in regulating protein synthesis. However, how leucine is able to increase protein synthesis is not entirely understood. Previously, it has been shown that 20-25 g of high-quality protein, such as that found in milk (whey), appears to be the amount of protein that maximizes the rate of muscle protein synthesis after performing a bout of resistance exercise. Thus, we aim to measure the synthesis of new muscle proteins after ingesting different amounts of protein and amino acids. We will measure muscle protein synthesis after consumption of the beverage a participant is randomized to in a leg that has done no exercise ( ie. a rested leg) and in the other leg that has done resistance exercise. Amino acids are 'strung-together' to make protein. The 'essential' amino acids must be consumed through food because our body cannot make them, thus they are consumed when you eat protein rich foods like milk or chicken. Leucine, isoleucine, and valine are simply 3 of the 8 essential amino acids that make up dietary protein. Unlike essential amino acids, 'non-essential' amino acids may be synthesized by the body, however they are also present in protein rich foods like chicken or milk. We aim to determine if it is the leucine content found in 25 g of whey protein that is primarily responsible for maximizing muscle protein synthesis at rest and following resistance exercise. We also wish to determine how muscle genes and metabolism respond to this protocol.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The processes of muscle protein synthesis (MPS) and muscle protein breakdown (MPB) occur concurrently. This constant protein turnover allows the muscle fiber to change its protein structure if loading demands or diet changes. The plasticity of skeletal muscle to respond to altered loading and contractile patterns is evidence of the capacity for remodeling that a fiber can undergo. It is quite well documented for example that mitochondrial content increases with endurance-type work. In contrast, heavier loading leads to less change in mitochondrial content but increases in myofibrillar proteins. All of the aforementioned phenotypic adaptations represent a re-patterning of the muscle's genetic expression patterns, protein translation, and processes for breakdown of existing protein structures to 'insert' the new proteins. A persistent muscle protein turnover also provides for a constant mechanism of protein 'maintenance' by removing damaged proteins and replacing them with new proteins. Damage to proteins can come about through oxidation or simply mechanical damage due to high forces during lengthening contractions. Regardless of the mechanism the balance between the processes of muscle protein synthesis (MPS) and muscle protein breakdown (MPB) will determine the net gain, loss, or no change of proteins in the myofiber.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Protein Synthesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Positive Control

Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control

Group Type EXPERIMENTAL

Positive Control

Intervention Type DIETARY_SUPPLEMENT

Subject consumes 25g of whey protein following unilateral exercise

Negative Control

Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control

Group Type EXPERIMENTAL

Negative Control

Intervention Type DIETARY_SUPPLEMENT

Subject consumes 6.25g of whey protein following unilateral exercise

Low Protein + Low Leucine Spike

Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike

Group Type EXPERIMENTAL

Low Protein Low Leucine Spike

Intervention Type DIETARY_SUPPLEMENT

Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise

Low Protein + High Leucine Spike

Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike

Group Type EXPERIMENTAL

Low Protein High Leucine Spike

Intervention Type DIETARY_SUPPLEMENT

Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise

Low Protein + High Leucine + BCAA Spike

Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike

Group Type EXPERIMENTAL

Low Protein + High Leucine + BCAA Spike

Intervention Type DIETARY_SUPPLEMENT

Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positive Control

Subject consumes 25g of whey protein following unilateral exercise

Intervention Type DIETARY_SUPPLEMENT

Negative Control

Subject consumes 6.25g of whey protein following unilateral exercise

Intervention Type DIETARY_SUPPLEMENT

Low Protein Low Leucine Spike

Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise

Intervention Type DIETARY_SUPPLEMENT

Low Protein High Leucine Spike

Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise

Intervention Type DIETARY_SUPPLEMENT

Low Protein + High Leucine + BCAA Spike

Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Healthy and physically active (as determined by medical and activity questionnaire)
* 18-35 years of age
* 70-90 kg body mass
* Having given informed consent

Exclusion Criteria

* Exhibiting health risk factors as identified on the health screening questionnaire
* Having any identified metabolic or intestinal disorders
* Tobacco use
* Aspirin use in the 4 days prior to the experimental trial
* Consumption of prescription medications or any performance enhancing agent
* Inability to endure the strenuous exercise bouts e.g. injuries
* Alcohol intake during the 48 hours prior to each of the testing days
* Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study
* Have given blood in the last three weeks
* Verbal confirmation that they have used a substance on the WADA banned list within the last year
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

McMaster University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stuart M Phillips, PhD

Role: PRINCIPAL_INVESTIGATOR

McMaster University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

McMaster University

Hamilton, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10.32.NRC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.